Printer Friendly

New Scientific Data on Allergan's BOTOX(R) (Botulinum Toxin Type A) Presented at the American Headache Society's 48th Annual Scientific Meeting.

New data on several potential therapeutic uses being investigated for Allergan's BOTOX(R) (Botulinum Toxin Type A) for the treatment of headache and migraine, as well as new epidemiological data on cervical dystonia and headache, will be presented at this year's American Headache Society (AHS) 48th Annual Scientific Meeting in Los Angeles, CA.

IRVINE, Calif., June 23 /PRNewswire/ --
 What: AHS 48th Annual Scientific Meeting: BOTOX(R) Scientific Sessions
 and Poster Presentations
 When: Thursday, June 22 - Sunday, June 25, 2006
 Where: Hyatt Regency Century Plaza Hotel & Spa, Los Angeles, California

PLEASE NOTE: All poster and presentation data are embargoed until time of

 BOTOX(R) and Headache/Migraine Poster Sessions

(All poster presentations noted below will take place on Friday, June 23 from 12:30 - 1:30 PM PDT in the California Show Room, and will be on display from 10 AM - 4 PM PDT)

Program to Assess Headache Treatment Strategies: An Observational Study of Botulinum Toxin Type A in the Preventive Treatment of Headache

[Poster F13] Silberstein SD, Mauskop A, Dodick DW, et al.

Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication Overuse [Poster F19] Freitag F, Diamond S, Diamond M, Urban G, Brooks KE.

A Randomized, Double-Blind Comparison of Botulinum Toxin Type A (BOTOX(R)) and Divalproex Sodium (Depakote(R)) for the Prophylactic Treatment of Episodic Migraine: A Pilot Study

[Poster F14] Porter JAH, Hill EG, McKenzie B, Porter K, Williams Guynn N.

Botulinum Toxin Type A Compared with Divalproex Sodium for the Prophylactic Treatment of Migraine: A 9-month Randomized, Evaluator-Masked Trial
 [Poster F15] Blumenfeld A, Schim J.

 Botulinum Toxin Type A (BOTOX(R)) for the Treatment of Migraine
 [Poster F17] Aurora SK.

Comparing the Relative Cost-Effectiveness of Oral Prophylactic Medications vs. Botulinum Toxin Type A (BOTOX(R)) in the Management of Migraine Headache: A Model Evaluating the Clinical and Economic Impact of Current Treatment Options

[Poster F16] Goldberg L.

Unilateralism as a Predictor of Response in Treatment of Chronic Headache Patients with Botulinum Toxin

[Poster F12] Lainez MJ, Gil R, Piera A, Lopez B, Santonja J.

Botulinum Toxin Type A (BoNT-A) for the Treatment of Cervicalgia and Headache: Results of a Single-Center, Randomized, Double-Blind, Active Placebo-Controlled Trial
 [Poster F18] Stillman M, Cherian N, John O, Elchani Z, Mays M, Kunkel R.

 Single Site BOTOX Injection: Effective Treatment for Migraine Headaches
 [Poster F20] Kriegler JS, Pashmini N, Reed DA, Guyuron B.

 Epidemiology of Cervical Dystonia Platform Presentation

The Prevalence of Headache Attributed to Craniocervical Dystonia in Patients with Craniocervical Dystonia: A Multicenter, Descriptive Epidemiology Study

[Platform OR12] McAllister P, Bigal ME, Molho E, Freeman A, Dimitrova R, Brin MF.
 * Friday, June 23 at 3:22 PM PDT; General Session Room

 About BOTOX(R)

BOTOX(R) is a medical product that contains tiny amounts of highly purified botulinum toxin protein refined from a bacterium. The product is administered in small therapeutic doses by injection directly into the affected area, and works by blocking the release of acetylcholine (a neurotransmitter that signals the muscles to contract) at the neuromuscular junction.

BOTOX(R) therapy was granted approval by the FDA in 1989 for the treatment of strabismus (crossed eyes) and blepharospasm (uncontrollable eye blinking) associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. BOTOX(R) has since received approval in December 2000 for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. In 2002, with dosing specific to treat frown lines between the eyebrows, the product was approved by the FDA for the temporary improvement in the appearance of moderate to severe glabellar lines (the vertical "frown lines" between the eyebrows) in adult men and women aged 65 and younger, under the name BOTOX(R) Cosmetic. More recently, in July 2004, BOTOX(R) was granted FDA approval for the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating) that is inadequately managed with topical agents.

Important Risk Information

BOTOX(R) and BOTOX(R) Cosmetic treatment is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any ingredient in the formulation. Serious and/or immediate hypersensitivity reactions have been rarely reported. These reactions include anaphylaxis, urticaria, soft tissue edema, and dyspnea. If such a reaction occurs further injection of BOTOX(R) or BOTOX(R) Cosmetic should be discontinued and appropriate medical therapy immediately instituted. BOTOX(R) and BOTOX(R) Cosmetic should only be diluted with 0.9 percent non-preserved sodium chloride. Individuals with peripheral motor neuropathic diseases (e.g., amyotrophic lateral sclerosis, or motor neuropathy) or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should only receive BOTOX(R) or BOTOX(R) Cosmetic with caution. Patients with neuromuscular disorders may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of BOTOX(R) or BOTOX(R) Cosmetic. There have been rare reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including cardiovascular disease. The exact relationship of these events to the botulinum toxin injection has not been established.
 BOTOX(R) for Blepharospasm in Patients greater than or equal to 12 Years
 of Age: Reduced blinking from BOTOX(R) injection of the orbicularis muscle
 can lead to corneal exposure, persistent epithelial defect and corneal
 perforation. The most frequently reported treatment-related adverse
 reactions in these patients are ptosis (20.8%), superficial punctate
 keratitis (6.3%) and eye dryness (6.3%).

 BOTOX(R) for Strabismus in Patients greater than or equal to 12 Years of
 Age: Inducing paralysis in one or more extraocular muscles may produce
 spatial disorientation, double vision or past pointing. The most commonly
 reported adverse effects are ptosis (16%) and vertical deviation (17%).

 BOTOX(R) for Cervical Dystonia in Adults: There have been rare cases of
 dysphagia severe enough to warrant the insertion of a gastric feeding
 tube. The most frequently reported adverse reactions in patients with
 cervical dystonia are dysphagia (19%), upper respiratory infection (12%),
 neck pain (11%), and headache (11%).

 BOTOX(R) for Severe Primary Axillary Hyperhidrosis Inadequately Managed
 with Topical Agents: Patients should be evaluated for potential causes of
 secondary hyperhidrosis (e.g., hyperthyroidism) to avoid symptomatic
 treatment of hyperhidrosis with out the diagnosis and/or treatment of the
 underlying disease. The most frequently reported adverse events (3 - 10%)
 are injection site pain and hemorrhage, non-axillary sweating, infection,
 pharyngitis, flu syndrome, headache, fever, neck or back pain, pruritus,
 and anxiety.

 BOTOX(R) Cosmetic for Temporary Improvement in the Appearance of Moderate
 to Severe Frown Lines Between the Brows in adults less than or equal to
 65: The most frequently reported adverse events are blepharoptosis (3.2%)
 and nausea (3%).

Full prescribing information for BOTOX(R) and BOTOX(R) Cosmetic is available at and

About Allergan, Inc.

With more than 55 years of experience providing high-quality, science- based products, Allergan, Inc., with headquarters in Irvine, California, develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives.

CONTACT: Cathy DiRamio of Allergan, Inc., +1-714-246-5551, office, or +1-310-498-1069, cell,

Web site:
COPYRIGHT 2006 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 23, 2006
Previous Article:Driving Profitability Through Strategic In-Licensing Partnerships.
Next Article:SkyePharma to Present at Jefferies Life Sciences Conference.

Related Articles
Researchers Announce Promising Results for the Prevention of Migraine Headaches.
News From the 45th Annual Scientific Meeting of the American Headache Society.
Allergan, the Makers of BOTOX(R), Receive UK Approval for VISTABEL for Cosmetic Use for the Treatment of Glabellar Lines (Vertical 'Frown' Lines...
Botulinum Toxin Type A (Botox(R)) Reduces Frequency of Migraines for Chronic Migraine Sufferers, According to New Study.
Video: Allergan, Inc. Marks 20 Years Since the First Approved Indications by the U.S. Food and Drug Administration for BOTOX(R) (Botulinum Toxin Type...
Reportlinker Adds World Botulinum Toxin Market Report.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters